PlainPharmaWatch

CMS Open Payments · Program Year 2024

Biofrontera Bioscience GmbH

Biofrontera Bioscience GmbH reported $1,342,984.83 in payments to 0 physicians and teaching hospitals across 150 transactions.

See the rankings → How this is sourced
$1.3M
Total payments
150
Transactions
0
Recipients
−$6.2K
General Payments vs PY2022

Biofrontera Bioscience GmbH reported $1,342,984.83 in payments to 0 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #547 of 1,925 reporting manufacturers (0.0% of all US industry payments), averaging $0.00 per recipient across 0 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Biofrontera Bioscience GmbH posts above-median payment volume among 1,925 companies reporting payments in CMS Open Payments PY2024.

#547
of 1,925 companies
0.0%
of all US industry payments
0
payment categories

Release-over-release change

General Payments changed from PY2022 to PY2023

Biofrontera Bioscience GmbH's CMS-reported General Payments decreased by $6.2K (−93.3%) from PY2022 to PY2023. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: BIOFRONTERA BIOSCIENCE GMBHPY2023: BIOFRONTERA BIOSCIENCE GMBHPY2024: Biofrontera Bioscience GmbH. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2022 vs PY2023

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2022$6.7KPY2023$448.00
PY2022
$6,651.00
PY2023
$448.00

How Biofrontera Bioscience GmbH ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Biofrontera Bioscience GmbH's total vs. every reporting company

CMS Open Payments, Program Year 2024

$1,342,985 Top 28% higher than 72% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). Below this entry. $752,621–$2,337,813: 263 reporting companies (14%). This entry sits in this band. $2,337,813–$7,261,783: 200 reporting companies (10%). Above this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). Above this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Biofrontera Bioscience GmbH

Averaging $9.0K per transaction and $0.00 per recipient, Biofrontera Bioscience GmbH's Program Year 2024 total comes to $1,342,984.83 across 150 transactions and 0 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #547 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

The 0-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). Payments are distributed across multiple categories without a dominant single type.

Payment Size Analysis

Average transaction size: $9.0K. Average per recipient: $0.00.

Total Amount

$1,342,984.83

Avg per Transaction

$9.0K

Avg per Recipient

$0.00

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Biofrontera Bioscience GmbH Share

0.0%

#547 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Biofrontera Bioscience GmbH

Vericel Corporation

$1.3M 3,314 recipients

Telix Pharmaceuticals

$1.3M 2,920 recipients

Leadiant Biosciences, Inc.

$1.3M 65 recipients

Surmodics, Inc.

$1.3M 2,433 recipients

C. R. Bard, Inc. & Subsidiaries

$1.3M 2,216 recipients

Trillium Therapeutics USA, LLC

$1.3M 0 recipients

Frequently Asked Questions

How much did Biofrontera Bioscience GmbH pay to physicians and hospitals in 2024? ▾
In Program Year 2024, CMS Open Payments recorded $1,342,984.83 from Biofrontera Bioscience GmbH to physicians and hospitals across 150 transactions - 0.0% of all industry payments reported that year.
How many physicians received payments from Biofrontera Bioscience GmbH? ▾
0 physicians and teaching hospitals received payments from Biofrontera Bioscience GmbH in 2024, averaging $0.00 per recipient.
What types of payments did Biofrontera Bioscience GmbH make? ▾
General payments from Biofrontera Bioscience GmbH span 0 distinct categories, covering things like consulting, meals, and travel.
How does Biofrontera Bioscience GmbH rank among pharmaceutical companies? ▾
Biofrontera Bioscience GmbH ranks #547 out of 1,925 companies by total payment amount in the CMS Open Payments database for 2024.
What is the average payment size from Biofrontera Bioscience GmbH? ▾
The average transaction from Biofrontera Bioscience GmbH was $9.0K in 2024. The company made 150 total transactions to 0 recipients.
Where does the payment data for Biofrontera Bioscience GmbH come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Biofrontera Bioscience GmbH's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.